CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02432963
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:33.237611+00:00
Published At: 2026-01-28T00:00:00+00:00
Record Updated At: 2026-01-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Adult Solid Neoplasm", "Bladder Carcinoma", "Colon Carcinoma", "Estrogen Receptor Negative", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "HER2/Neu Negative", "Melanoma", "Non-Small Cell Lung Carcinoma", "Pancreatic Carcinoma", "Progesterone Receptor Negative", "Rectal Carcinoma", "Renal Cell Carcinoma", "Soft Tissue Sarcoma", "Triple-Negative Breast Carcinoma", "TP53 Gene Mutation", "Unresectable Solid Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-28"
protocolSection.identificationModule.nctId: "NCT02432963"
protocolSection.identificationModule.officialTitle: "A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.